


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on May 9, 2007

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney



1645  
IPW

INFORMATION DISCLOSURE  
STATEMENT

Examining Group 1645

Patent Application

Docket No. C&R-101

Serial No. 10/534,242

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (not yet assigned)  
Art Unit : 1645  
Applicants : Richard Joseph Fagan, Christopher Benjamin Phelps, Tania Maria Rodrigues,  
Christine Power, Jadwiga Bienkowska  
Serial No. : 10/534,242  
Filed : May 9, 2005  
Conf. No. : 2652  
For : Alpha Macroglobulin Family Member

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC §371. The applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notification of Acceptance of the Application under 35 USC 371 (Form PCT/DO/EO/903). The Notification does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 CFR §1.56, the applicants hereby

request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

The applicants have also listed on form PTO/SB/08 numerous references which have not been cited in the International Search Report. Copies of these references are also enclosed with this IDS.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik

A Professional Association

P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (3 pages); copies of references cited



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,242
				Filing Date	May 9, 2005
				First Named Inventor	Richard Joseph Fagan
				Art Unit	1645
Examiner Name					
Sheet	1	of	3	Attorney Docket Number	C&R-101

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1	WO 02/079398 A2 (on CD)		10-10-2002	Curagen Corp.	All
	F					
	F					
	F					
	F					
	F					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Application Number

10/534,242

Filing Date

May 9, 2005

First Named Inventor

Richard Joseph Fagan

Group Art Unit

1645

Examiner Name

Attorney Docket Number

C&amp;R-101

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	NIELSEN, K. <i>et al.</i> "Amino acid sequence of hen ovomacroglobulin (ovostatin) deduced from cloned cDNA" <i>J. DNA Sequencing and Mapping</i> , 1994, 5(2):111-119.	
	R2	NAGASE, H. <i>et al.</i> "Ovostatin a novel proteinase inhibitor from chicken egg white 1. Purification physicochemical properties and tissue distribution of ovostatin" <i>J. Biol. Chem.</i> , 1983, 258(12):7481-7489.	
	R3	QAZI, U. <i>et al.</i> "On the structural changes of native human alpha2-macroglobulin upon proteinase entrapment: Three-dimensional structure of the half-transformed molecule" <i>J. Biol. Chem.</i> , 1998, 273(15):8987-8993.	
	R4	RAMOS, A. M. <i>et al.</i> "Trypanosoma cruzi Cruzipain and Membrane-Bound Cysteine Proteinase Isoform(s) Interacts with Human $\alpha_2$ -macroglobulin and Pregnancy Zone Protein", <i>Experimental Parasitology</i> , 2002, pp. 121-130, Vol. 100.	
	R5	LIN, M. <i>et al.</i> "Cell Surface Antigen CD109 is a Novel Member of the $\alpha_2$ Macroglobulin/C3, C4, C5 Family of Thioester-containing Proteins", <i>Blood</i> , March 1, 2002, pp. 1683-1691, Vol. 99, No. 5.	
	R6	SHERMAN, S. K. <i>et al.</i> "Role of the Complement System in Ischaemic Heart Disease", <i>BioDrugs</i> , 2001, pp. 595-607, Vol. 15, No. 9.	
	R7	ASAMI, T. <i>et al.</i> "Study on Proteinase-Inhibiting Capacity of Plasma $\alpha_2$ -Macroglobulin in Idiopathic Nephrotic Syndrome", <i>Nephron</i> , 1996, pp. 512-517, Vol. 72.	
	R8	PETERSON, C. M. " $\alpha_2$ -Macroglobulin and Pregnancy Zone Protein", <i>Danish Medical Bulletin</i> , September 1993, pp. 409-446, Vol. 40, No. 4.	
	R9	HONG, T. <i>et al.</i> "A Study on the Serum Pregnancy Zone Protein Levels in Pregnant Women and Patients with Gynecological Tumors", <i>Chinese Medical Journal</i> , 1994, pp. 910-914, Vol. 107, No. 12.	
	R10	ZAPPIA, M. <i>et al.</i> "Genetic Association of $\alpha_2$ -Macroglobulin Polymorphisms with AD in Southern Italy", <i>Neurology</i> , September 2002, pp. 756-758, Vol. 59.	
	R11	GENNARO, R. <i>et al.</i> "C5a Fragment of Bovine Complement", <i>Eur. J. Biochem.</i> , 1986, pp. 77-86, Vol. 155.	
	R12	FRITZINGER, D. C. <i>et al.</i> "Primary Structure of Cobra Complement Component C3", <i>The Journal of Immunology</i> , December 1, 1992, pp. 3554-3562, Vol. 149, No. 11.	
	R13	SANDOVAL, A. <i>et al.</i> "Distal Recognition Site for Classical Pathway Convertase Located in the C345C/Netrin Module of Complement Component C5", <i>The Journal of Immunology</i> , 2000, pp. 1066-1073, Vol. 165.	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/534,242	
			Filing Date	May 9, 2005	
			First Named Inventor	Richard Joseph Fagan	
			Group Art Unit	1645	
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	C&R-101

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	R14	NIELSEN, K. L. <i>et al.</i> "Identification of Residues in $\alpha$ -Macroglobulins Important for Binding to the $\alpha_2$ -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein", <i>The Journal of Biological Chemistry</i> , May 31, 1996, pp. 12909-12912, Vol. 271, No. 22.		
	R15	BHATIA, M. <i>et al.</i> "Complement Factor C5a Exerts an Anti-Inflammatory Effect in Acute Pancreatitis and Associated Lung Injury", <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> , 2001, pp. G974-G978, Vol. 280.		
	R16	SOTTRUP-JENSEN, L. " $\alpha$ -Macroglobulins: Structure, Shape, and Mechanism of Proteinase Complex Formation", <i>The Journal of Biological Chemistry</i> , July 15, 1989, pp. 11539-11542, Vol. 264, No. 20.		
	R17	NICOLETTI, G. <i>et al.</i> "No Evidence of Association Between the Alpha-2 Macroglobulin Gene and Parkinson's Disease in a Case-Control Sample", <i>Neuroscience Letters</i> , 2002, pp. 65-67, Vol. 328.		
	R18	O'BARR, S. <i>et al.</i> "The C5a Complement Activation Peptide Increase IL-1 $\beta$ and IL-6 Release from Amyloid- $\beta$ Primed Human Monocytes: Implications for Alzheimer's Disease", <i>Journal of Neuroimmunology</i> , 2000, pp. 87-94, Vol. 109.		
	R19	CISLO, M. <i>et al.</i> "Allelic Distribution of Complement Components BF, C4A, C4B, and C3 in <i>Psoriasis vulgaris</i> ", <i>Immunology Letters</i> , 2002, pp. 145-149, Vol. 80.		
	R20	TANG, G. <i>et al.</i> "Alpha-2 Macroglobulin I1000V Polymorphism in Chinese Sporadic Alzheimer's Disease and Parkinson's Disease", <i>Neuroscience Letters</i> , 2002, pp. 195-197, Vol. 328.		
	R21	KÖHL, J. "Anaphylatoxins and Infectious and Non-Infectious Inflammatory Diseases", <i>Molecular Immunology</i> , 2001, pp. 175-187, Vol. 38.		
	R22	GHEBREMEDHIN, E. <i>et al.</i> "Genetic Association of Argrophilic Grain Disease with Polymorphisms in Alpha-2 Macroglobulin and Low-Density Lipoprotein Receptor-Related Protein Genes", <i>Neuropathology and Applied Neurobiology</i> , 2002, pp. 308-313, Vol. 28.		
	R23	EGGERTSEN, G. <i>et al.</i> "Sequence of Rat $\alpha_1$ -Macroglobulin, a Broad-range Proteinase Inhibitor from the $\alpha$ -Macroglobulin-complement Family", <i>Mol. Biol. Med.</i> , 1991, pp. 287-302, Vol. 8.		
	R24	OGATA, R. T. <i>et al.</i> "Sequence of the Gene for Murine Complement Component C4", <i>The Journal of Biological Chemistry</i> , October 5, 1989, pp. 16565-16572, Vol. 264, No. 28.		
	R25	NAGASE, H. <i>et al.</i> "Evidence for a Thiol Ester in Duck Ovostatin (Ovomacroglobulin)", <i>The Journal of Biological Chemistry</i> , January 25, 1986, pp. 1421-1426, Vol. 261, No. 3.		
	R			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.